BETHLEHEM, Pa., Jan. 3, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has added a third computational module to its DOSE program. The DOSE program uses a combination of empirical data and proprietary modeling tools to efficiently arrive at the optimal drug product for a given API and dosage form. Previously, Particle Sciences implemented software solutions for calculating and predicting solubilization systems for API's and modeling the solubility of a given API in candidate polymers for drug-eluting polymeric devices. A second module introduced in mid-2011 calculates inter-particle forces in dispersed systems, and leads to the design of stable nano or micro particle suspensions. The third and latest addition accurately models the elution of a given API from a non-degrading polymeric device, such as an implant or an intravaginal ring. Based on well-established mathematics and a set of base measurements, this latest addition allows Particle Sciences to significantly reduce the time needed for prototyping drug-device combination products.
According to Dr. Andrew Loxley, Particle Sciences' Director of New Technologies, "These proprietary computational tools, combined with Particle Sciences' industry-leading formulation and process capabilities, give our clients a true competitive advantage, allowing them to get to the right product faster. Particle Sciences has also institutionalized the use of Design of Experiments (DOE) in the product development process. While there is no replacement for actual prototyping and measurement, the systematic use of these modeling tools to guide the DOE approach streamlines our efforts providing our clients with the most expedient path to clinically relevant products."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visitwww.particlesciences.com, email firstname.lastname@example.org contact us at (610) 861- 4701 for information.
Contact: Maureen Mattera
(610) 861- 4701
SOURCE Particle Sciences Inc.